PL376900A1 - Zastosowanie kombinacji zawierającej nienukleozydowy inhibitor odwrotnej transkryptazy (NNRTI) i inhibitor cytochromu P450, taki jak inhibitor proteazy - Google Patents

Zastosowanie kombinacji zawierającej nienukleozydowy inhibitor odwrotnej transkryptazy (NNRTI) i inhibitor cytochromu P450, taki jak inhibitor proteazy

Info

Publication number
PL376900A1
PL376900A1 PL376900A PL37690003A PL376900A1 PL 376900 A1 PL376900 A1 PL 376900A1 PL 376900 A PL376900 A PL 376900A PL 37690003 A PL37690003 A PL 37690003A PL 376900 A1 PL376900 A1 PL 376900A1
Authority
PL
Poland
Prior art keywords
inhibitor
nnrti
cytochrome
reverse transcriptase
protease inhibitors
Prior art date
Application number
PL376900A
Other languages
English (en)
Inventor
Michael Graham Cordingley
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL376900A1 publication Critical patent/PL376900A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL376900A 2002-12-16 2003-12-15 Zastosowanie kombinacji zawierającej nienukleozydowy inhibitor odwrotnej transkryptazy (NNRTI) i inhibitor cytochromu P450, taki jak inhibitor proteazy PL376900A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16

Publications (1)

Publication Number Publication Date
PL376900A1 true PL376900A1 (pl) 2006-01-09

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376900A PL376900A1 (pl) 2002-12-16 2003-12-15 Zastosowanie kombinacji zawierającej nienukleozydowy inhibitor odwrotnej transkryptazy (NNRTI) i inhibitor cytochromu P450, taki jak inhibitor proteazy

Country Status (20)

Country Link
US (2) US20040152625A1 (pl)
EP (1) EP1575595A1 (pl)
JP (1) JP2006511538A (pl)
KR (1) KR20050085681A (pl)
CN (1) CN1726041A (pl)
AU (1) AU2003296647A1 (pl)
BR (1) BR0317095A (pl)
CA (1) CA2510143A1 (pl)
EA (1) EA200500894A1 (pl)
EC (1) ECSP055854A (pl)
HR (1) HRP20050557A2 (pl)
IL (1) IL169099A0 (pl)
MX (1) MXPA05005773A (pl)
NO (1) NO20053455L (pl)
NZ (1) NZ541187A (pl)
PL (1) PL376900A1 (pl)
RS (1) RS20050461A (pl)
UA (1) UA81003C2 (pl)
WO (1) WO2004054586A1 (pl)
ZA (1) ZA200502947B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
EP1971615B1 (en) 2005-11-30 2014-01-01 TaiMed Biologics, Inc. Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
WO2008078200A2 (en) 2006-09-21 2008-07-03 Ambrilia Biopharma Inc. Protease inhibitors
SG10201400235PA (en) 2009-02-27 2014-07-30 Enanta Pharm Inc Hepatitis c virus inhibitors
LT2421527T (lt) 2009-04-25 2018-09-10 F. Hoffmann-La Roche Ag Farmakokinetinių savybių pagerinimo būdai
JP5639155B2 (ja) 2009-05-13 2014-12-10 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビターとしての大環状化合物
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2001518899A (ja) * 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
EP1126847A1 (en) * 1998-11-04 2001-08-29 PHARMACIA & UPJOHN COMPANY Method for improving the pharmacokinetics of tipranavir
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
US7105510B2 (en) * 2002-09-19 2006-09-12 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
HRP20050557A2 (en) 2006-05-31
JP2006511538A (ja) 2006-04-06
ZA200502947B (en) 2008-01-30
EA200500894A1 (ru) 2006-02-24
ECSP055854A (es) 2006-01-16
KR20050085681A (ko) 2005-08-29
WO2004054586A1 (en) 2004-07-01
NZ541187A (en) 2007-12-21
NO20053455L (no) 2005-08-10
US20040152625A1 (en) 2004-08-05
US20080096832A1 (en) 2008-04-24
IL169099A0 (en) 2007-07-04
AU2003296647A1 (en) 2004-07-09
CA2510143A1 (en) 2004-07-01
MXPA05005773A (es) 2005-08-16
CN1726041A (zh) 2006-01-25
UA81003C2 (en) 2007-11-26
BR0317095A (pt) 2005-10-25
EP1575595A1 (en) 2005-09-21
RS20050461A (en) 2007-08-03

Similar Documents

Publication Publication Date Title
IL169099A0 (en) Use of a combination containing a non-nucleoside revrse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
HK1080849A1 (en) Non-nucleoside reverse transcriptase inhibitors
PL378556A1 (pl) Nienukleozydowe inhibitory odwrotnej transkryptazy
AU2003269628A1 (en) Non-nucleoside reverse transcriptase inhibitors
SG148179A1 (en) Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
TWI372619B (en) Non-nucleoside reverse transcriptase inhibitors
NO20053215D0 (no) Pyrazolderivater med anvendelse som COX-1-inhibitorer.
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
NO20053144D0 (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
HK1111155A1 (en) Non-nucleoside reverse transcriptase inhibitors
IL162353A0 (en) Combination of cytochrome p450 dependent protease inhibitors
AU2003257284A1 (en) Aromatic derivatives as hiv aspartyl protease inhibitors
AU2003234630A1 (en) Cysteine protease inhibitors
AU7037001A (en) Non-nucleoside reverse transcriptase inhibitors
AU2003290735A1 (en) Inhibitors of monoamine uptake
HK1081551A1 (en) Process and intermediates for making non-nucleoside hiv-1 reverse transcriptase inhibitors
AP1878A (en) Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors.
AU2003243765A8 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
AU2003269984A1 (en) Protease inhibitors
PL372226A1 (pl) Pochodne pirydynoamidu jako inhibitory monoaminooksydazy (MAO-B)
AU2003206588A1 (en) Urea derivatives as hiv aspartyl protease inhibitors
AU2003260908A1 (en) Pyrazole derivatives as reverse transcriptase inhibitors
AU2003263738A1 (en) Protease inhibitors
HRP20040886A2 (en) Non-nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)